Clinical trials
Low Risk Prostate Cancer clinical trials
Below are recruiting low risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 165 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT06325046Recruiting
Adaptive radiation therapy for localized prostate cancer
This trial tests a type of radiation that adapts to your body's changes during treatment. It is for men with low- to intermediate-risk prostate cancer that hasn't spread.
Albert Lea, MinnesotaAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Adelaide, South AustraliaAges 18 years+ - NCT06331013Recruiting
CyberKnife Radiation for Prostate Cancer
This trial tests a high-precision radiation treatment (CyberKnife SBRT) for prostate cancer that is still within the prostate. It aims to see if a very short course of radiation works well with fewer side effects.
MilanAges 18–80 - NCT06437574RecruitingPhase 2
Cholesterol-lowering and immune response in prostate cancer
This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT06709326Recruiting
Collecting blood cells to study prostate cancer
This study uses a blood filtering procedure (apheresis) to collect prostate cancer cells from your blood for detailed analysis. It may help researchers understand why some prostate cancers spread, which could lead to better treatments. There are three groups: men with metastatic prostate cancer, men with PSA relapse after prostatectomy, and healthy volunteers.
Umeå, Norrlands University HospitalAges 18–81 - NCT06733350RecruitingPhase 4
Testosterone therapy for low testosterone in men with low-risk prostate cancer
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Buffalo, New YorkAges 18 years+ - NCT06759701RecruitingEarly Phase 1
Weight loss drug before prostate cancer surgery pilot study
This study tests if taking tirzepatide (a weight loss medicine) before prostate removal surgery is safe and helpful for overweight men with intermediate-risk prostate cancer. It aims to see if losing weight can improve surgery outcomes.
Houston, TexasAges 18 years+ - NCT06862856Recruiting
PET Scan for Men With Very Low PSA After Prostate Surgery
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT07112781Recruiting
Single dose radiation for early prostate cancer
This trial tests whether a single, high dose of radiation can treat low- to intermediate-risk prostate cancer. It may be a shorter and more convenient option for eligible patients.
MoscowAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07168616Recruiting
PSMA PET imaging for active surveillance in low-risk prostate cancer
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Istanbul, TurkeyAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07231627Recruiting
Using AI to improve prostate cancer detection from MRI
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
Little Rock, ArkansasAges 40 years+ - NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+ - NCT07285057RecruitingPhase 2
New PET scan for men with low-risk prostate cancer on active surveillance
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
New York, New YorkAges 18 years+ - NCT07339943Recruiting
Focal laser ablation for intermediate-risk prostate cancer
This trial tests a new way to treat intermediate-risk prostate cancer using a targeted laser guided by micro-ultrasound and MRI. It aims to see if this less invasive approach is safe and effective for men who have not had prior prostate cancer treatments.
Toronto, OntarioAges 40–85 - NCT07344844Recruiting
Custom Stereo Radiography for Early Prostate Cancer
This study tests a precise type of radiation (stereotactic radiotherapy) for men with early-stage prostate cancer. It aims to see if using custom radiation beams improves outcomes while reducing side effects.
Saint-DenisAges 60 years+ - NCT07348367Recruiting
Comparing two prostate cancer surgeries for low-risk patients
This trial compares two types of prostate surgery (standard removal vs. precision removal) in men with low- or intermediate-risk prostate cancer. It aims to see which surgery preserves urinary and sexual function while still effectively treating the cancer.
Detroit, MichiganAges Any age - NCT01492972RecruitingPhase 3
Lighter radiation, with or without hormone suppression
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Scottsdale, ArizonaAges 18 years+ - NCT02391051RecruitingPhase 2
Targeted radiation for low-risk prostate cancer
This trial tests a focused form of radiation placed inside the prostate to treat only the cancer area in people with low-risk prostate cancer. It aims to control the cancer while limiting treatment to a smaller area.
ErlangenAges 18 years+ - NCT02759744Enrolling by invitation
Laser treatment for certain prostate tumors guided by MRI images
This trial tests whether a precisely targeted laser procedure—guided by MRI images—can treat prostate cancer. It may help some men who have a certain type and location of tumor while aiming to avoid nearby sensitive structures.
Bethesda, MarylandAges 18–100 - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+
Hear when a new Low Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low risk prostate cancer?
- Yes. Clin2 currently lists 165 recruiting low risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.